Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents

Rheumatology International

Volumn 35, Issue 10, 2015, Pages 1733-1737

  Eroglu, Fehime Kara ^a,b   Beşbaş, Nesrin ^a   Topaloglu, Rezan ^a   Ozen, Seza ^a  

^a Department of Pediatric Nephrology Rheumatology ^*  (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Anakinra; Anti IL1; Canakinumab; Child; Colchicine; Etanercept; Familial Mediterranean fever

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; ETANERCEPT; INTERLEUKIN 1 ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; AMYLOIDOSIS; ARTHRITIS; ARTICLE; AUTOINFLAMMATORY DISEASE; AUTOINFLAMMATORY DISEASE ACTIVITY INDEX; BIOLOGICAL THERAPY; CHILD; CLINICAL ARTICLE; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; FEVER; FOLLOW UP; HUMAN; INJECTION SITE PAIN; KIDNEY AMYLOIDOSIS; LABORATORY TEST; MYALGIA; NEUTROPENIA; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TURKISH CITIZEN; URTICARIA; FEMALE; MALE; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; COLCHICINE; ETANERCEPT; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941994738     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-015-3293-2     Document Type: Article

References (20)

1. Ozen S, Bilginer Y (2014) A clinical guide to autoinflammatory diseases: Familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 10:135–147
2. Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M et al (2013) Evidence-based recommendations for the practical management of Familial Mediterranean fever. Semin Arthritis Rheum 43:387–391
3. Twig G, Livneh A, Vivante A, Afek A, Shamiss A, Derazne E et al (2014) Mortality risk factors associated with Familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann Rheum Dis 73:704–709
4. Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U et al (2007) Colchicine use in children and adolescents with Familial Mediterranean fever: literature review and consensus statement. Pediatrics 119:474–483
5. Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C et al (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72:678–685
6. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F et al (2005) Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84(1):1–11
7. Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J et al (2014) Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 73(12):2168–2173. doi:10.1136/annrheumdis-2013-203666
8. Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A et al (2014) FMF50: a score for assessing outcome in Familial Mediterranean fever. Ann Rheum Dis 73(5):897–901. doi:10.1136/annrheumdis-2013-204719
9. Ben-Chetrit E, Ozdogan H (2008) Non-response to colchicine in FMF definition, causes and suggested solutions. Clin Exp Rheumatol 26(4 Suppl 50):S49–S51
10. Hacihamdioglu DO, Ozen S (2012) Canakinumab induces remission in a patient with resistant Familial Mediterranean fever. Rheumatology (Oxford) 51:1041
11. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M (2011) Anti-interleukin 1 treatment for patients with Familial Mediterranean fever resistant to colchicine. J Rheumatol 38(3):516–518
12. Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol 29(2):209–210
13. Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R, Langevitz P, Livneh A (2004) Colchicine nonresponsiveness in Familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 33(4):273–282
14. Bezalel Y, Gershoni-Baruch R, Dagan E, Lidar M, Livneh A (2009) The 3435T polymorphism in the ABCB1 gene and colchicine unresponsiveness in Familial Mediterranean fever. Clin Exp Rheumatol 27(2 Suppl 53):S103–S104
15. Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U, Karadag O, Hayran M, Ertenli AI, Bozkurt A, Kiraz S (2007) Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in Familial Mediterranean fever. J Rheumatol 34(7):1540–1544
16. Akgul O, Kilic E, Kilic G, Ozgocmen S (2013) Efficacy and safety of biologic treatments in Familial Mediterranean fever. Am J Med Sci 346(2):137–141
17. Omenetti A, Carta S, Delfino L, Martini A, Gattorno M, Rubartelli A (2014) Increased NLRP3-dependent interleukin 1beta secretion in patients with Familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis 73:462–469
18. Soylemezoglu O, Arga M, Fidan K, Gonen S, Emeksiz HC, Hasanoglu E, Buyan N (2010) Unresponsiveness to colchicine therapy in patients with Familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol 37:182–189
19. Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P et al (2012) Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 12:72–76
20. Kuemmerle-Deschner JB, Wittkowski H, Koetter I, Lohse P, Ummenhofer K et al (2013) Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther 15:R64